Search

Your search keyword '"Han, Baohui"' showing total 1,300 results
Start Over Author "Han, Baohui"
1,300 results on '"Han, Baohui"'

1. Clinical and imaging analyses of primary mediastinal yolk sac tumor

Author

MA Meili, TENG Jiajun, GAO Zhiqiang, SHI Chunlei, ZHONG Hua, and HAN Baohui

Subjects
mediastinum, yolk sac tumor, computerized tomography, alpha fetoprotein, chemotherapy, Medicine
Abstract

Objective·To summarize the clinical features, imaging features, and diagnosis and treatment experience of primary mediastinal yolk sac tumor (YST).Methods·Data of 29 patients with primary mediastinal YST, who attended Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine from September 2016 to May 2023, were collected and comprehensively analyzed, including imaging examination results, serum indicators, pathology reports and treatment methods.Results·There were 22 cases of pure YST and 7 cases of mixed YST comprising 28 males and 1 female. The mean age of onset was (24.5±5.9) years. The initial symptoms were chest tightness (34.5%), chest pain (27.8%), cough (34.5%), expectoration (34.5%) and no specific symptoms (24.1%). Chest computerized tomography (CT) enhancement showed that all the 29 lesions were located in the anterior mediastinum. The maximum diameter of the lesions ranged from 5.6 cm to 18.2 cm. The lesions were irregular in shape, uneven in density, partially cystic and solid in density. The enhancement scan showed the solid part was slightly and moderately enhanced, and the low-density area was not enhanced. Tumor boundary was not clear because tumors often compressed and invaded surrounding tissues. Among the 29 newly diagnosed patients, serum alpha-fetoprotein (AFP) was significantly increased in 28 cases (1 case was not tested). Patients received multidisciplinary comprehensive treatment, including chemotherapy (25/29), surgery (26/29), and radiotherapy (8/29). Seven patients directly received surgery after diagnosis. Nineteen patients received chemotherapy first and then surgery; 16 (84.2%) cases were evaluated as lesion shrinkage after chemotherapy. After surgery, 73.1% (19/26) patients had a significant decrease in serum AFP. After chemotherapy, 56.0% (14/25) patients had decreased serum AFP.Conclusion·Primary mediastinal YST usually occurs in middle-aged and young men, with certain clinical and radiographic features and elevated serum AFP, which requires multidisciplinary comprehensive treatment.

Published
2024
Full Text
View/download PDF

3. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study

Author

Zhang, Bo, Liu, Hongyu, Shi, Chunlei, Gao, Zhiqiang, Zhong, Runbo, Gu, Aiqin, Chu, Tianqing, Wang, Huimin, Xiong, Liwen, Zhang, Wei, Zhang, Xueyan, Yan, Bo, Teng, Jiajun, Wang, Weimin, Bai, Hao, Qiao, Rong, Cheng, Lei, Kuang, Yanbin, Zhao, Ruiying, Zhong, Hua, and Han, Baohui

Published
2024
Full Text
View/download PDF

6. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Author

Ren, Shengxiang, Xiong, Anwen, Yu, Jia, Wang, Xicheng, Han, Baohui, Pan, Yueyin, Zhao, Jun, Cheng, Yufeng, Hu, Sheng, Liu, Tianshu, Li, Yalun, Cheng, Ying, Feng, Jifeng, Yi, Shanyong, Gu, Shanzhi, Gao, Shegan, Luo, Yongzhong, Liu, Ying, Liu, Caigang, Duan, Huijie, Wang, Shuni, Yang, Xinfeng, Fan, Jia, and Zhou, Caicun

Published
2024
Full Text
View/download PDF

7. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

Author

Han, Baohui, Feinstein, Trevor, Shi, Yuankai, Cheng, Gongyan, Yao, Yu, Hu, Chunhong, Shi, Jianhua, Feng, Jifeng, Wu, Huijuan, Cheng, Ying, Guo, Qi-sen, Jie, Zhijun, Ye, Feng, Zhang, Yiping, Liu, Zhihua, Mao, Weidong, Zhang, Liangming, Lu, Junguo, Zhao, Jun, Bazhenova, Lyudmila, Ruiz, Jimmy, Kloecker, Goetz, Kalmadi, R Sujith, Oliff, Ira, Wong, Matthew, Liu, Bin, Wu, Yanping, Huang, Lan, Sun, Yan, Luo, Feng, Zhou, Jian-ying, Pan, Hongming, Wang, Huaqing, Liu, Chunling, Cao, Lejie, Huang, Chao Hui, Thara, Eddie, Li, Xiaoling, Jiang, Da, Mowat, Rex B, Hrom, John S, Nagrial, Adnan, Jain, Vikram, Karim, Nagla A, Shunyakov, Leonid V, Kiberu, Andrew, Jennens, Ross, Lloyd, Ken, Wang, Zhongkun, Du, Lihua, Li, Helen, Chen, Gongyan, Kloecker, Goetz H, Sujith, Kalmadi R, and Oliff, Ira A

Published
2024
Full Text
View/download PDF

8. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer

Author

Xu, Jiachen, Wan, Rui, Cai, Yiran, Cai, Shangli, Wu, Lin, Li, Baolan, Duan, Jianchun, Cheng, Ying, Li, Xiaoling, Wang, Xicheng, Han, Liang, Wu, Xiaohong, Fan, Yun, Yu, Yan, Lv, Dongqing, Shi, Jianhua, Huang, Jianjin, Zhou, Shaozhang, Han, Baohui, Sun, Guogui, Guo, Qisen, Ji, Youxin, Zhu, Xiaoli, Hu, Sheng, Zhang, Wei, Wang, Qiming, Jia, Yuming, Wang, Ziping, Song, Yong, Wu, Jingxun, Shi, Meiqi, Li, Xingya, Han, Zhigang, Liu, Yunpeng, Yu, Zhuang, Liu, An-Wen, Wang, Xiuwen, Zhou, Caicun, Zhong, Diansheng, Miao, Liyun, Zhang, Zhihong, Zhao, Hui, Yang, Jun, Wang, Dong, Wang, Yingyi, Li, Qiang, Zhang, Xiaodong, Ji, Mei, Yang, Zhenzhou, Cui, Jiuwei, Gao, Beili, Wang, Buhai, Liu, Hu, Nie, Lei, He, Mei, Jin, Shi, Gu, Wei, Shu, Yongqian, Zhou, Tong, Feng, Jian, Yang, Xinmei, Huang, Cheng, Zhu, Bo, Yao, Yu, Yu, Jianjun, Yao, Sheng, Shen, Runxi, Wang, Zhijie, and Wang, Jie

Published
2024
Full Text
View/download PDF

10. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

Author

Yang, James Chih-Hsin, Han, Baohui, De La Mora Jiménez, Emmanuel, Lee, Jong-Seok, Koralewski, Piotr, Karadurmus, Nuri, Sugawara, Shunichi, Livi, Lorenzo, Basappa, Naveen S., Quantin, Xavier, Dudnik, Julia, Ortiz, Diego Moran, Mekhail, Tarek, Okpara, Chinyere E., Dutcus, Corina, Zimmer, Zachary, Samkari, Ayman, Bhagwati, Niyati, and Csőszi, Tibor

Published
2024
Full Text
View/download PDF

11. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial

Author

Zhong, Hua, Sun, Shengjie, Chen, Jianhua, Wang, Ziping, Zhao, Yanqiu, Zhang, Guojun, Chen, Gongyan, Zhou, Ming, Zhou, Jianying, Du, Yingying, Wu, Lin, Xu, Zhi, Mei, Xiaodong, Zhang, Weidong, He, Jingdong, Cui, Jiuwei, Zhang, Zhihong, Luo, Hui, Liu, Weiyou, Sun, Meili, Wu, Jingxun, Shen, Yongchun, Zhang, Shucai, Yang, Nong, Wang, Mengzhao, Lu, Junguo, Li, Kai, Yao, Weirong, Sun, Qian, Yue, Hongmei, Wang, Lin, Ye, Sheng, Li, Bin, Zhuang, Xibin, Pan, Yueyin, Zhang, Min, Shu, Yongqian, He, Zhiyong, Pan, Lei, Ling, Yang, Liu, Shengming, Zhang, Qi, Jiao, Shunchang, and Han, Baohui

Published
2024
Full Text
View/download PDF

12. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

Author

Zhao, Shen, Zhuang, Wu, Han, Baohui, Song, Zhengbo, Guo, Wei, Luo, Feng, Wu, Lin, Hu, Yi, Wang, Huijuan, Dong, Xiaorong, Jiang, Da, Wang, Mingxia, Miao, Liyun, Wang, Qian, Zhang, Junping, Fu, Zhenming, Huang, Yihua, Xu, Chunwei, Hu, Longyu, Li, Lei, Hu, Rong, Yang, Yang, Li, Mengke, Yang, Xiugao, Zhang, Li, Huang, Yan, and Fang, Wenfeng

Published
2023
Full Text
View/download PDF

17. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Author

Lee, Siow Ming, Schulz, Christian, Prabhash, Kumar, Kowalski, Dariusz, Szczesna, Aleksandra, Han, Baohui, Rittmeyer, Achim, Talbot, Toby, Vicente, David, Califano, Raffaele, Cortinovis, Diego, Le, Anh Tuan, Huang, Dingzhi, Liu, Geoffrey, Cappuzzo, Federico, Reyes Contreras, Jessica, Reck, Martin, Palmero, Ramon, Mak, Milena Perez, Hu, Youyou, Morris, Stefanie, Höglander, Elen, Connors, Mary, Biggane, Alice M, Vollan, Hans Kristian, and Peters, Solange

Published
2023
Full Text
View/download PDF

19. China lung cancer screening (CLUS) version 2.0 with new techniques implemented: Artificial intelligence, circulating molecular biomarkers and autofluorescence bronchoscopy

Author

Zhang, Yanwei, Qian, Fangfei, Teng, Jiajun, Wang, Huimin, Yu, Hong, Chen, Qunhui, Wang, Lan, Zhu, Jingjing, Yu, Yinghong, Yuan, Junyi, Cai, Weiming, Xu, Ning, Zhu, Huixian, Lu, Yun, Yao, Mingling, Zhu, Jiayu, Dong, Juanjuan, Yu, lingming, Ren, Hua, Yang, Jiancheng, Sun, Jiayuan, Zhong, Hua, and Han, Baohui

Published
2023
Full Text
View/download PDF

20. Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

Author

Zhou, Qing, Soo, Ross A., Chang, Gee-Chen, Chiu, Chao-Hua, Hayashi, Hidetoshi, Kim, Sang-We, Teraoka, Shunsuke, Goto, Yasushi, Zhou, Jianying, Ho-Fun Lee, Victor, Kim, Dong-Wan, Han, Baohui, Chung Man Ho, James, Lin, Chia-Chi, Lu, Shun, Polli, Anna, Calella, Anna Maria, Martini, Jean-François, Wong, Chew Hooi, Mok, Tony, Kim, Hye Ryun, and Wu, Yi-Long

Published
2023
Full Text
View/download PDF

34. The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification.

Author

Zheng, Liang, Hu, Fang, Nie, Wei, Lu, Jun, Zhang, Bo, Xu, Jianlin, Wang, Shuyuan, Li, Ying, Zheng, Xiaoxuan, Zhang, Wei, Shen, Yinchen, Zhong, Runbo, Chu, Tianqing, Han, Baohui, Zhong, Hua, and Zhang, Xueyan

Subjects
IMMUNE checkpoint inhibitors, LINOLEIC acid, BLOOD platelet activation, LIPID metabolism, LUNG cancer
Abstract

Background: The 9th edition of the TNM Classification for lung cancer delineates M1c into two subcategories: M1c1 (Multiple extrathoracic lesions within a single organ system) and M1c2 (Multiple extrathoracic lesions involving multiple organ systems). Existing research indicates that patients with lung cancer in stage M1c1 exhibit superior overall survival compared to those in stage M1c2. The primary frontline therapy for patients with advanced non‐small cell lung cancer (NSCLC), lacking driver gene mutations, involves the use of immune checkpoint inhibitors (ICIs) combined with chemotherapy. Nevertheless, a dearth of evidence exists regarding potential survival disparities between NSCLC patients with M1c1 and M1c2 undergoing first‐line immune‐chemotherapy, and reliable biomarkers for predicting treatment outcomes are elusive. Serum metabolic profiles may elucidate distinct prognostic mechanisms, necessitating the identification of divergent metabolites in M1c1 and M1c2 undergoing combination therapy. This study seeks to scrutinize survival discrepancies between various metastatic patterns (M1c1 and M1c2) and pinpoint metabolites associated with treatment outcomes in NSCLC patients undergoing first‐line ICIs combined with chemotherapy. Method: In this study, 33 NSCLC patients lacking driver gene mutations diagnosed with M1c1, and 22 similarly diagnosed with M1c2 according to the 9th edition of TNM Classification, were enrolled. These patients received first‐line PD‐1 inhibitor plus chemotherapy. The relationship between metastatic patterns and progression‐free survival (PFS) in patients undergoing combination therapy was analyzed using univariate and multivariate Cox regression models. Serum samples were obtained from all patients before treatment initiation for untargeted metabolomics analysis, aiming to identify differential metabolites. Results: In the univariate analysis of PFS, NSCLC patients in M1c1 receiving first‐line PD‐1 inhibitor plus chemotherapy exhibited an extended PFS (HR = 0.49, 95% CI, 0.27–0.88, p = 0.017). In multivariate PFS analyses, these M1c1 patients receiving first‐line PD‐1 inhibitor plus chemotherapy also demonstrated prolonged PFS (HR = 0.45, 95% CI, 0.22–0.92, p = 0.028). The serum metabolic profiles of M1c1 and M1c2 undergoing first‐line PD‐1 inhibitors plus chemotherapy displayed notable distinctions. In comparison to M1c1 patients, M1c2 patients exhibited alterations in various pathways pretreatment, including platelet activation, linoleic acid metabolism, and the VEGF signaling pathway. Diminished levels of lipid‐associated metabolites (diacylglycerol, sphingomyelin) were correlated with adverse outcomes. Conclusion: NSCLC patients in M1c1, devoid of driver gene mutations, receiving first‐line PD‐1 inhibitors combined with chemotherapy, experienced superior outcomes compared to M1c2 patients. Moreover, metabolomic profiles strongly correlated with the prognosis of these patients, and M1c2 patients with unfavorable outcomes manifested distinct changes in metabolic pathways before treatment. These changes predominantly involved alterations in lipid metabolism, such as decreased diacylglycerol and sphingomyelin, which may impact tumor migration and invasion. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Author

Yang, Yunpeng, Sun, Jiya, Wang, Zhehai, Fang, Jian, Yu, Qitao, Han, Baohui, Cang, Shundong, Chen, Gongyan, Mei, Xiaodong, Yang, Zhixiong, Ma, Rui, Bi, Minghong, Ren, Xiubao, Zhou, Jianying, Li, Baolan, Song, Yong, Feng, Jifeng, Li, Juan, He, Zhiyong, Zhou, Rui, Li, Weimin, Lu, You, Zhou, Hui, Wang, Shuyan, Sun, Luyao, Puig, Oscar, Mancao, Christoph, Peng, Bo, Fang, Wenfeng, Xu, Wei, and Zhang, Li

Published
2021
Full Text
View/download PDF

44. Physicians’ Knowledge of Pulmonary Rehabilitation in China: A Cross-Sectional Study

Author

Pan,Feng, Lu,Ai-ting, Mao,Xiaowei, Hu,Fang, Zhang,Hai, Han,Baohui, Pan,Feng, Lu,Ai-ting, Mao,Xiaowei, Hu,Fang, Zhang,Hai, and Han,Baohui

Abstract

Feng Pan,1,* Ai-ting Lu,1,2,* Xiaowei Mao,1,* Fang Hu,1 Hai Zhang,1 Baohui Han1 1Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Baohui Han, Email 18930858216@163.comObjective: To investigate the knowledge of pulmonary rehabilitation (PR) among physicians involved in pulmonary disease management.Methods: This multi-regional cross-sectional survey was conducted from December 12, 2019 to January 22, 2020. The participants were enrolled and an electronic questionnaire was exclusively sent to the members of the Lung Cancer Special Committee of the China Medicine Education Association through the WeChat platform. Multivariable logistic regression analysis was performed to explore the associated factors of high PR knowledge scores (≥ 18 points).Results: From the 858 valid questionnaires, the routine implementation of PR was only reported for 16.95% of physicians. The main reason hindering the implementation of PR for patients was the limited knowledge and awareness of PR among the physicians involved (69.1%). A total of 618 and 240 physicians had high and low knowledge scores, respectively. Multivariable analysis suggests that the self-perception of PR knowledge (OR = 1.89, 95% CI: 1.32– 2.771, P = 0.001) was independently associated with high knowledge scores, while having no theoretical knowledge of PR was associated with poor knowledge scores (OR = 0.43, 95% CI: 0.26– 0.72, P = 0.001).Conclusion: Inadequate knowledge of pulmonary rehabilitation is evident among physicians who are involved in pulmonary disease management in China. This underscores the need for more

Published
2024

46. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

Author

Xu, Yan, Xiang, Zheng, Alnaggar, Mohammed, Kouakanou, Léonce, Li, Jiawei, He, Junyi, Yang, Jiashuang, Hu, Yi, Chen, Yan, Lin, Li, Hao, Jianlei, Li, Jingxia, Chen, Jibing, Li, Man, Wu, Qingling, Peters, Christian, Zhou, Qinghua, Li, Jianshuang, Liang, Yingqing, Wang, Xiaohua, Han, Baohui, Ma, Meili, Kabelitz, Dieter, Xu, Kecheng, Tu, Wenwei, Wu, Yangzhe, and Yin, Zhinan

Published
2021
Full Text
View/download PDF

47. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Author

Yang, Yunpeng, Wang, Zhehai, Fang, Jian, Yu, Qitao, Han, Baohui, Cang, Shundong, Chen, Gongyan, Mei, Xiaodong, Yang, Zhixiong, Ma, Rui, Bi, Minghong, Ren, Xiubao, Zhou, Jianying, Li, Baolan, Song, Yong, Feng, Jifeng, Li, Juan, He, Zhiyong, Zhou, Rui, Li, Weimin, Lu, You, Wang, Yingyi, Wang, Lijun, Yang, Nong, Zhang, Yan, Yu, Zhuang, Zhao, Yanqiu, Xie, Conghua, Cheng, Ying, Zhou, Hui, Wang, Shuyan, Zhu, Donglei, Zhang, Wen, and Zhang, Li

Published
2020
Full Text
View/download PDF

49. Chinese experts’ consensus on the Internet of Things-aided diagnosis and treatment of coronavirus disease 2019 (COVID-19)

Author

Bai, Li, Yang, Dawei, Wang, Xun, Tong, Lin, Zhu, Xiaodan, Zhong, Nanshan, Bai, Chunxue, Powell, Charles A., Chen, Rongchang, Zhou, Jian, Song, Yuanlin, Zhou, Xin, Zhu, Huili, Han, Baohui, Li, Qiang, Shi, Guochao, Li, Shengqing, Wang, Changhui, Qiu, Zhongmin, Zhang, Yong, Xu, Yu, Liu, Jie, Zhang, Ding, Wu, Chaomin, Li, Jing, Yu, Jinming, Wang, Jiwei, Dong, Chunling, Wang, Yaoli, Wang, Qi, Zhang, Lichuan, Zhang, Min, Ma, Xia, Zhao, Lin, Yu, Wencheng, Xu, Tao, Jin, Yang, Wang, Xiongbiao, Wang, Yuehong, Jiang, Yan, Chen, Hong, Xiao, Kui, Zhang, Xiaoju, Song, Zhenju, Zhang, Ziqiang, Wu, Xueling, Sun, Jiayuan, Shen, Yao, Ye, Maosong, Tu, Chunlin, Jiang, Jinjun, Yu, Hai, and Tan, Fei

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results